Immunotherapy toxicity survey

UCLH cancer academy has been funded to develop multidisciplinary education on check point inhibitors and immune related adverse events.  We are very keen that the materials we produced are helpful to the whole BOPA membership.  To understand where the gaps are we have developed a questionnaire (see link below).  It will take less than 10 minutes to complete and will be really helpful for us to understand where the gaps are at different hospitals.  Please could this be completed by June 2nd.  If you have any questions or would like to keep in touch with our work, then please email Elly on [email protected].

https://forms.office.com/e/rAAj4DzjNK

Latest News

By UK SACT Board on 9th November 2026

New UK SACT Board National Intrathecal and Intraventricular SACT Guidance

Dear colleagues, We are pleased to share the newly published UK SACT Board National Guidance on the Safe Administration of Systemic Anti-Cancer Therapies via the Intrathecal or Intraventricular Routes. This…

Read article
By BOPA Executive Committee on 9th November 2026

BOPA members flying the flag for cancer pharmacy at ESMO 2026

It was fantastic to see BOPA members representing cancer pharmacy at ESMO Congress 2026 in Madrid, which brought together the global cancer community from 23 to 27 October to share…

Read article
By BOPA Executive Committee on 30th October 2026

Publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs

We are delighted to recognise the recent publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs, a new book bringing together expertise from oncology pharmacy professionals across the world.…

Read article
By BOPA Executive Committee on 30th October 2026

Acute and Supportive Oncology Clinical Consensus Statement

BOPA welcomes the Acute and Supportive Oncology Clinical Consensus Statement, to which we were pleased to contribute. It will be a benchmark for the sector, bringing direction and consistency as…

Read article